To study the correlation between blood lactate level and neonatal hyperbilirubinemia and to predict the severity of NHB in neonates
Abstract
Objective: To study the correlation between blood lactate level and hyperbilirubinemia in neonates and to analyze the predictive value of blood lactate level for the severity of NHB in neonates.
Methods: A total of 123 children diagnosed with Neonatal hyperbilirubinemia (NHB) admitted to the obstetrics department from October 2021 to October 2022 were selected as the NHB group, and according to the severity of the disease, they were divided into mild, moderate, and severe. Fifty healthy neonates born in the department of obstetrics were selected as the control group. The levels of glucose-6-phosphate dehydrogenase (G6PD), creatine kinase isoenzyme (CK-MB), β2-microglobulin (β2-MG), aspartate aminotransferase (AST), blood lactic acid and total bilirubin in serum were compared. Pearson correlation analysis was used to analyze the correlation between blood lactate level and bilirubin level, and the ROC curve was used to determine the predictive value of blood lactate level for the severity of NHB in neonates.
Results: The NHB group had significantly higher levels of AST, CK-MB, β2-MG, blood lactic acid, and total bilirubin than the NHB group (P < 0.05). G6PD level was significantly lower (P < 0.05). According to Pearson, blood lactic acid level was positively correlated with total bilirubin level (r = 0.604, P < 0.001). The ROC curve showed that the AUC of blood lactic acid level in predicting the severity of NHB was 0.873, which was higher than that of total bilirubin alone (P < 0.05).
Conclusions: Neonates with NHB have higher serum levels of AST, CK-MB, β2-MG, blood lactate, and total bilirubin, while lower G6PD levels. The serum level of blood lactate is positively correlated with the total bilirubin level, which can be used to observe the severity of NHB in neonates.
References
[2]Du L, Ma X, Shen X, et al. Neonatal hyperbilirubinemia management: Clinical assessment of bilirubin production[J]. Semin Perinatol. 2021 Feb;45(1):151351.
[3]Hegyi T, Kleinfeld A. Neonatal hyperbilirubinemia and the role of unbound bilirubin[J]. Matern Fetal Neonatal Med. 2022 Dec;35(25):9201-9207.
[4]Boskabadi H, Rakhshanizadeh F, Zakerihamidi M. Evaluation of Maternal Risk Factors in Neonatal Hyperbilirubinemia[J]. Arch Iran Med. 2020 Feb 1;23(2):128–140.
[5]Cortey A, Renesme L, Raignoux J, et al. Ictère à bilirubine non conjuguée du nouveau-né de 35 semaines et plus : du dépistage au suivi après sortie de la maternité. Recommandations pour la pratique clinique [Management of jaundice in the newborn≥35 GW: From screening to follow-up after discharge. Guidelines for clinical practice][J]. Arch Pediatr. 2017 Feb;24(2):192-203. French.
[6]Kemper AR, Newman TB, Slaughter JL, et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation[J]. Pediatrics. 2022 Sep 1;150(3):e2022058859.
[7]Olusanya BO, Kaplan M, Hansen TWR. Neonatal hyperbilirubinaemia: a global perspective[J]. Lancet Child Adolesc Health. 2018 Aug;2(8):610-620.
[8]Alkén J, Håkansson S, Ekéus C, et al. Rates of Extreme Neonatal Hyperbilirubinemia and Kernicterus in Children and Adherence to National Guidelines for Screening, Diagnosis, and Treatment in Sweden[J]. AMA Netw Open. 2019 Mar 1;2(3):e190858.
[9]Juschten J, Bos LDJ, de Grooth HJ, et al. Incidence, Clinical Characteristics and Outcomes of Early Hyperbilirubinemia in Critically Ill Patients: Insights From the MARS Study[J]. Shock. 2022 Feb 1;57(2):161-167.
[10]Horn D, Ehret D, Gautham KS,et al. Sunlight for the prevention and treatment of hyperbilirubinemia in term and late preterm neonates[J]. Cochrane Database Syst Rev. 2021 Jul 6;7(7): CD013277.
[11]Shiota A, Mikamo H. [Expectations for Pharmacists and Pharmacy Education in AST Activities][J]. Yakugaku Zasshi. 2021;141(11):1249-1251. Japanese.
[12]Minamidate N, Takashima N, Suzuki T. The impact of CK-MB elevation in patients with acute type A aortic dissection with coronary artery involvement[J]. Cardiothorac Surg. 2022 Jul 6;17(1):169.
[13]Puthumana J, Thiessen-Philbrook H, Xu L,et al. Biomarkers of inflammation and repair in kidney disease progression[J]. Clin Invest. 2021 Feb 1;131(3):e139927.
[14]Mizuiri S, Nishizawa Y, Doi T, et al. Convection volume, β2-microglobulin and α1-microglobulin reduction ratios, and body composition in pre-dilution online haemodiafiltration[J]. Nephrology (Carlton). 2022 Jul;27(7):601-609.
[15]Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency[J]. Blood. 2020 Sep 10;136(11):1225-1240.
[16]Schipper HM, Song W, Tavitian A, et al. The sinister face of heme oxygenase-1 in brain aging and disease[J]. Prog Neurobiol. 2019 Jan;172:40-70.
[17]Pavlovic Markovic A, Stojkovic Lalosevic M, Mijac DD, et al. Jaundice as a Diagnostic and Therapeutic Problem: A General Practitioner's Approach[J]. Dig Dis. 2022;40(3):362-369.
[18]Kumagai S, Koyama S, Itahashi K, et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments[J]. Cancer Cell. 2022 Feb 14;40(2):201-218.e9.
[19]Vincent JL, Bakker J. Blood lactate levels in sepsis: in 8 questions[J]. Curr Opin Crit Care. 2021 Jun 1;27(3):298-302.
[20]Qattea I, Farghaly MAA, Elgendy M, et al. Neonatal hyperbilirubinemia and bilirubin neurotoxicity in hospitalized neonates: analysis of the US Database[J]. Pediatr Res. 2022 Jun;91(7):1662-1668.
[21]Rathore S, Kumar Vk C, R S. A critical review on neonatal hyperbilirubinemia-an Ayurvedic perspective[J].Ayurveda Integr Med. 2020 Apr-Jun;11(2):190-196.
[22]Hulzebos CV, Vitek L, Coda Zabetta CD, et al. Diagnostic methods for neonatal hyperbilirubinemia: benefits, limitations, requirements, and novel developments[J]. Pediatr Res. 2021 Aug;90(2):277-283.
[23]Zhang M, Tang J, He Y, et al. Systematic review of global clinical practice guidelines for neonatal hyperbilirubinemia. BMJ Open. 2021 Jan 19;11(1):e040182.
Copyright (c) 2025 Gangqiang Zhang, Kun Shao, Yun-heng Zhou
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.